BSEResult5d ago · 14 Aug 2026, 04:35 pm
Unaudited financial results for Quarter ended on 30 June 2026.
Genomic Valley Biotech Ltd · 539206
✦ AI SummaryResults
Genomic Valley Biotech Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The company's management has approved the results, which have been reviewed by the statutory auditor ANDROS & CO. The results are based on the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) and have been prepared in accordance with the Listing Regulations.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Genomic Valley Biotech Ltd - 539206 - Results-Financial Results For Quarter Ended On 30 June 2026.
Attachments (1)
📄pdf
Download →
e75a4409-ad1a-4bc6-b043-1fe5f34574c7.pdf
View document text
14th August, 2026
The Manager,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
Scrip Code: 539206; Company Symbol: GVBL
Sub: Outcome of the Board meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 held on today i.e. 14th August 2026.
Dear Sir/Madam,
This is to inform you that the Board of Directors of the Company at their meeting held on Wednesday,
14th August 2026, at the Corporate office of the Company situated at G-74, Pushkar Enclave, Paschim
Vihar, Delhi - 110063 to consider and approve the following matter(s): -
1. Considered and approved the standalone Un-audited financial results of the company for the
quarter ended on 30th June 2026. A copy of the said standalone un-audited financial results along
with the Limited review report from Statutory Auditor thereon is enclosed herewith.
The meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 03:40 P.M.
This is for your information and record please.
Thanking you,
Yours sincerely,
For Genomic Valley Biotech Limited
Yogesh Agrawal
Managing Director
DIN : 01165288
ANDROS & CO.
90L , Pearls Omaxe,PIot B-1
Chartered Accountants NSP , Pitampura , Delhi 110034
Email: briibhushan_ca @yah oo,co.in
Phone 47068981, 9811075811
LIMITED REVIEW REPORT
The Baard of Directors of
Genomic Valley Biotech Limited,
4 K.M" Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehlil- Bahadurgarh, District-|haiiar, Haryana- XZ45*7 .
1. Introduction
We have reviewed the accompanying statement of unaudited financial results for the Quarter
ended on fune 3A,ZA26 ('the statement') of Genomic Valley Biotech Limited ['the Company')
attached herewith, being submitted by the Company pursuant to the requirements of
Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, as
amended ("Listing Regulations").
This Statement is the responsibility of the Cornpany's Management and approved by the Board
of Directors, has been prepared in accordance with the recognition and rneasurement
principles laid down in the Indian Accounting Standard 34 ('lnd AS 34'J, Interim Financial
Reporting', prescribed under Section 133 of the Companies Act, 2AL3, read with relevant rules
issued thereunder and other accounting principles generally accepted in India. Our
responsibility is to express a conclusion on the Statement based on our review.
2. Scope o.f Review
We Conducted our review in accordance with the Standard on Review Engagements (SRE)
241A, 'Review of lnterim Financial Information performed by the Independent Auditor of the
Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial
information consists of making inquiries, primarily of persons responsible for financial and
accounting matters, and applying analytical and other review procedures.
A review is substantially less in scope than an audit conducted in accordance with Standards
on Auditing (Sas) and consequently hoes not enable us to obtain assurance that we would
become aware of all significant matters that might be identified in an audit. Accordingly, we do
not express and audit opinion.
3. Conclusion
Based on our review conducted as above, nothing has come to our attention that causes us to
believe that the accompanying Statement prepared in accordance with the applicable Indian
Accounting Standard ('lnd AS') prescribed under Section 133 of the Companies Act, 2013, read
with relevant rules issued thereunder and other recognized accounting practices and policies,
has not disclosed the information required to be disclosed in terms of Regulation 33 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2AL5, including the
manner in which it is to be disclosed, or that it contains any material misstatement.
For ANDROS & CO.
Chartered Accountants
FRN: 008976N
ICA Brii bhushan Garg)
(Partner)
(Membership No.-084865)
Place: Delhi
Date: 1+-08-2 07-6
Peer Review certificate no: 019517
: 2608 4865-IITXCX -4853
UDIN